World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
85
Citations
43139
World Ranking
14372
National Ranking
7266

Overview

Amita Patnaik is affiliated with the University of Chicago in the United States and has a substantial body of research primarily within the field of Medicine. Their work focuses notably on oncology and related subfields, with 141 publications in Oncology, 51 in Pulmonary and Respiratory Medicine, 33 in Radiology, Nuclear Medicine and Imaging, 31 in Molecular Biology, and 30 in Immunology.

The scientist's research has concentrated on several major topics including Cancer Immunotherapy and Biomarkers, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research, Lung Cancer Treatments and Mutations, and Colorectal Cancer Treatments and Studies.

Frequent publication venues for Amita Patnaik include the Journal of Clinical Oncology with 38 publications, Cancer Research with 33, Regular and Young Investigator Award Abstracts with 13, Annals of Oncology with 12, and Clinical Cancer Research with 7.

Their recent published papers reflect topics on cancer therapy and treatment strategies across multiple tumor types:

  • Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC (2020), Journal of Thoracic Oncology
  • Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study (2022), The Lancet Oncology
  • Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody (2021), Clinical Cancer Research
  • Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial (2023), Clinical Cancer Research
  • The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads (2020), American Society of Clinical Oncology Educational Book

Amita Patnaik has collaborated extensively with a number of researchers. Frequent co-authors include Kyriakos P. Papadopoulos, Drew Rasco, Nehal J. Lakhani, Alyssa Simonson, and Manish Sharma, reflecting ongoing partnerships in clinical and translational oncology research.

Best Publications

  • Pembrolizumab for the treatment of non-small cell lung cancer

    Edward B. Garon;Naiyer A. Rizvi;Rina Hui;Natasha Leighl

  • Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

    Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi

  • Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial

    Caroline Robert;Antoni Ribas;Jedd D. Wolchok;F. Stephen Hodi

  • Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    Corey J Langer;Shirish M Gadgeel;Hossein Borghaei;Vassiliki A Papadimitrakopoulou

  • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

    Mark J. Ratain;Tim Eisen;Walter M. Stadler;Keith T. Flaherty

  • Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

    Antoni Ribas;Omid Hamid;Adil Daud;F. Stephen Hodi

  • Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

    O. Hamid;C. Robert;C. Robert;A. Daud;F.S. Hodi

  • Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

    Edward B. Garon;Matthew D. Hellmann;Naiyer A. Rizvi;Enric Carcereny

  • First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

    Timothy A. Yap;Li Yan;Amita Patnaik;Ivy Fearen

  • Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

    F. Stephen Hodi;Wen Jen Hwu;Richard Kefford;Jeffrey S. Weber

  • Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

    Amita Patnaik;S. Peter Kang;Drew Rasco;Kyriakos P. Papadopoulos

  • Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

    Adil I. Daud;Jedd D. Wolchok;Caroline Robert;Wen Jen Hwu

  • Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

    Amita Patnaik;Lee S. Rosen;Sara M. Tolaney;Anthony W. Tolcher

  • The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer

    Toshio Shimizu;Anthony W. Tolcher;Kyriakos P. Papadopoulos;Muralidhar Beeram

  • First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.

    Branimir I. Sikic;Nehal Lakhani;Amita Patnaik;Sumit A. Shah

  • Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

    Caroline Robert;Caroline Robert;Antoni Ribas;Omid Hamid;Adil Daud

  • Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.

    Alain C. Mita;Louis J. Denis;Eric K. Rowinsky;Johann S. DeBono

  • Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1

    Anthony W. Tolcher;Monica Mita;Neal J. Meropol;Margaret von Mehren

  • Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

    A W Tolcher;S L Gerson;L Denis;C Geyer

  • Raf: A Strategic Target for Therapeutic Development Against Cancer

    Muralidhar Beeram;Amita Patnaik;Eric K. Rowinsky

Frequent Co-Authors

Anthony W. Tolcher
Anthony W. Tolcher Texas Oncology
Richard F. Kefford
Richard F. Kefford Macquarie University
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Adil Daud
Adil Daud University of California, San Francisco
Caroline Robert
Caroline Robert University of Paris-Saclay
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Johanna C. Bendell
Johanna C. Bendell Sarah Cannon Research Institute
Patricia LoRusso
Patricia LoRusso Yale University
Peter Hersey
Peter Hersey University of Sydney
Omid Hamid
Omid Hamid Cedars-Sinai Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering studying medicine in the USA, you may also want to explore alternative healthcare career options and flexible learning paths. Many students are turning to accelerated programs, such as direct entry msn programs online, which allow non-nurses to earn a master’s in nursing and start a new career quickly.

For those seeking less competitive admission processes, you can find easiest nursing programs to get into, offering accessible options for prospective students who may not meet stringent entrance requirements.

Not everyone wants a direct patient care role—medical billing and coding is a fast-growing field with many online study choices. There are accredited medical billing and coding schools with financial aid to help you launch your career without overwhelming costs.

Finally, test requirements can be a barrier. Some nursing schools that don't require teas or hesi exams offer a streamlined path for students who are ready to take the next step but want to avoid additional standardized testing.

Best Scientists Citing Amita Patnaik

Trending Scientists

Recently Published Articles